Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

Dasatinib Use and Risk of Cytomegalovirus Reactivation After Allogeneic Hematopoietic-Cell Transplantation

2017; Oxford University Press; Volume: 65; Issue: 3 Linguagem: Inglês

10.1093/cid/cix325

ISSN

1537-6591

Autores

Daniel P. Prestes, Esther Arbona, Alexandra Nevett-Fernandez, Ann E. Woolley, Vincent T. Ho, Sophia Koo, Lindsey R. Baden, John Koreth, Sarah P. Hammond, Nicolas C. Issa, Francisco M. Marty,

Tópico(s)

Acute Lymphoblastic Leukemia research

Resumo

Viral infections have been reported with dasatinib use, but its cytomegalovirus risk after hematopoietic-cell transplantation (HCT) is not known. We found that post-HCT dasatinib use increased the risk of cytomegalovirus reactivation (adjusted hazard ratio, 7.65; 95% confidence interval, 1.84–31.7), controlling for acute graft-versus-host disease, in 109 patients with Philadelphia-chromosome-positive malignancies.

Referência(s)